Following the mandate given by the European Commission to the SCCS in the context of the safety assessment of substances with potential endocrine disrupting properties, the Scientific Committee has just published its final opinion on Salicylic Acid. It was adopted during the plenary meeting of 6-7 June 2023.
Background
The last SCCS assessment was performed in view the classification of Salicylic Acid as a CMR2 (Repr.2) substance under the CLP Regulation and in accordance to the provisions laid out in Article 15 of the Cosmetics Regulation.
It is currently regulated under Annex III (entry 98) and Annex V (entry 3), with specific maximum concentrations and conditions of use.
The Commission asked the SCCS to carry out a safety assessment of Salicylic acid in the light of the latest information provided by industry to demonstrate the safety of the substance.
In December 2022, the CSSC published its preliminary Opinion.
For an exhaustive background information, see the articles
• Endocrine disruptors: 2nd call for data from the European Commission, CosmeticOBS, 22 February 2021
• Methylparaben, Benzyl Salicylate, Salicylic Acid: requests for SCCS Opinions, CosmeticOBS, 14 February 2022
• Salicylic Acid: preliminary Opinion of the SCCS, CosmeticOBS, 20 December 2022
This Opinion has been subject to a commenting period of eight weeks after its initial publication (from 15 December 2022 until 17 February 2023). Comments received during this period were considered by the SCCS. For this Opinion, main changes occurred in the following sections: 3.3.1.2, 3.3.2.1, 3.3.2.2. SCCS …
